Novo Nordisk Thailand implements blockchain-based digital system for GLP-1 Product to combat counterfeit and enhance patient safety
Novo Nordisk Thailand today announced the successful implementation of a blockchain-based traceability solution that can verify the authenticity of OzempicR throughout the supply chain. The new digital system aims to combat the growing issue of counterfeit spread nowadays and enhance patient safety.
Illegally manufactured products may contain the wrong or incorrectly dosed active pharmaceutical ingredients or even harmful substances, potentially leading to serious adverse effects in patients. Such counterfeit products are widely distributed, especially on unregulated online platforms and social media which are difficult to control, putting consumers at risk of harm from substandard medications.
Novo Nordisk Thailand has therefore implemented ‘eZTracker’ developed by Zuellig Pharma, designed to ensure the authenticity of pharmaceutical products. This solution involves the application of a 2D data matrix sticker on each sales pack, making every pack uniquely identifiable and traceable.
Mr. Enrico Cañal Bruland, General Manager of Novo Nordisk Pharma (Thailand) Ltd., stated: “Novo Nordisk has been committed to raising awareness about counterfeit medications. With patient safety as our top priority, we have introduced a new digital system in Thailand to verify the authenticity of our products. Through our partnership with Zuellig Pharma, we aim to ensure patient safety by combating counterfeit products with the highest standards.”
Healthcare professionals, pharmacists, and patients can easily verify the authenticity of OzempicR products in real-time by simply scanning the 2D QR pink sticker on the box or by entering the product’s code using the eZTracker application. A successful scan indicates that the product is genuine and will display detailed product information. If the scan fails, it is likely a counterfeit product. Users are encouraged to report any unsuccessful scans through the eZTracker app to help combat counterfeit medications and ensure the safety of all users.
Mr Cañal Bruland added: “This marks a significant milestone in our efforts to combat counterfeit products and build confidence for both patients and healthcare professionals. Novo Nordisk Thailand is confident that this solution will enhance trust as well as the safety and well-being of those relying on Novo Nordisk products.”
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
